L
Luke Whitesell
Researcher at Massachusetts Institute of Technology
Publications - 75
Citations - 8817
Luke Whitesell is an academic researcher from Massachusetts Institute of Technology. The author has contributed to research in topics: HSF1 & Drug resistance. The author has an hindex of 36, co-authored 75 publications receiving 7756 citations. Previous affiliations of Luke Whitesell include University of Arizona & University of Toronto.
Papers
More filters
Patent
Indazole derivatives and uses thereof
Benjamin Vincent,Luke Whitesell,Susan Lindquist,Willmen Youngsaye,Stephen L. Buchwald,Jean-Baptiste Langlois,Partha Pratim Nag,Amal Ting,Barbara Morgan,Benito Munoz,Sivaraman Dandapani,Bruce Tidor,Raja Srinivas +12 more
TL;DR: In this article, the authors proposed a method for treating and/or preventing a fungal or protozoan infection, inhibiting the activity of an enzyme, killing a fungus, or stopping the growth of a fungus or a protozoon.
Patent
Hsf1 and hsf1 cancer signature set genes and uses relating thereto
TL;DR: In this paper, the Heat Shock Protein-1 (HSF1) gene and HSF1 gene products were used for tumor diagnosis, prognosis, treatment-specific prediction, treatment selection, or drug discovery.
Journal ArticleDOI
A New Dihydroxanthenone from a Plant‐Associated Strain of the Fungus Chaetomium globosum Demonstrates Anticancer Activity.
E. M. Kithsiri Wijeratne,Thomas J. Turbyville,Anne Fritz,Luke Whitesell,A. A. Leslie Gunatilaka +4 more
TL;DR: In this paper, a bioassay-guided fractionation of a cytotoxic EtOAc extract of the fungal strain, Chaetomium globosum, inhabiting the rhizosphere of the Christmas cactus, Opuntia leptocaulis, of the Sonoran desert afforded a new dihydroxanthenone, globosuxanthone A (1), a new tetrahydroxanthone B (2), 2-hydroxyvertixanthone (5), and two known anthraquinones (6 and 7).
Patent
Hsf1 in tumor stroma
TL;DR: In this paper, the Heat Shock Protein-1 (HSF1) gene and HSF1 gene products in tumor stroma were used for tumor prognosis, treatment-specific prediction, or treatment selection.
Identification of small molecules that selectively inhibit fluconazole-resistant Candida albicans in the presence of fluconazole but not in its absence - Probe 2
Cathy L Hartland,Willmen Youngsaye,Barbara J. Morgan,Amal Ting,Partha P. Nag,Sara J. Buhrlage,Stephen Johnston,Joshua A. Bittker,Benjamin Vincent,Luke Whitesell,Sivaraman Dandapani,Lawrence MacPherson,Benito Munoz,Michelle Palmer,Susan Lindquist,Stuart L. Schreiber +15 more
TL;DR: In this paper, the authors identify compounds that selectively reverse fluconazole resistance in a Candida albicans clinical isolate, while having no antifungal activity when administered as a single agent.